
FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), a bivalent RSV vaccine, for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18 to 59…












